

## Special Issue

# Novel Drug Design and Activity Targeting Ion Channels

### Message from the Guest Editors

Ion channels (ICs) are transmembrane ionotropic receptors that pass mono- and/or divalent ions when a chemical messenger, such as a neurotransmitter, activates the receptor. ICs are involved in a wide range of neurological disorders of high clinical significance, including nicotine addiction, depression and Alzheimer's disease. Drugs targeting ICs can bind competitively or noncompetitively to activate or inhibit an agonist response. Molecules binding in distinct modalities can reveal how a specific IC functions, which can facilitate the development of novel therapies. In recent decades, ICs have been prime targets for drug discovery efforts, resulting in some clinical translation success, including anaesthetics, analgesics, antidepressants and addiction therapies. ICs remain one of the most important proteins used to study structure–activity relationships (SARs) and targets for novel drug design efforts. This Special Issue invites papers on drug action and/or drug design for drugs targeting ICs.

---

### Guest Editors

Dr. Maegan Weltzin

1. College of Natural Science and Mathematics, Department of Chemistry and Biochemistry, CNSM Division of Research, The University of Alaska Fairbanks, Fairbanks, AK, USA
2. Barrow Neurological Institute, Phoenix, AZ, USA

Dr. Dinesh Indurthi

University at Buffalo, The State University of New York, Buffalo, NY, USA

---

### Deadline for manuscript submissions

closed (31 August 2023)



# Molecules

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.6**

**CiteScore 8.6**

**Indexed in PubMed**




[mdpi.com/si/131408](http://mdpi.com/si/131408)

*Molecules*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
molecules@mdpi.com

[mdpi.com/journal/  
molecules](http://mdpi.com/journal/molecules)





# Molecules

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/journal/  
molecules](http://mdpi.com/journal/molecules)

## About the Journal

### Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

---

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).

